Our vision is to develop novel, safe, and effective immunotherapies for the treatment and prevention of cancer, allergy, infectious disease, and autoimmune disease. We currently have two programs in Phase I: INI-2004, a TLR4 agonist for allergy and INI-4001, a TLR7/8 agonist for oncology. Our novel compounds are designed to target relevant innate immune pathways to reprogram the immune system and drive a therapeutic response.
Inimmune has completed a Phase I clinical trial evaluating the safety and tolerability of INI-2004 (a TLR4 agonist) as a treatment for allergic rhinitis. Inimmune also has an ongoing Phase I clinical trial evaluating the safety and tolerability of INI-4001 (a TLR7/8 agonist) as a cancer treatment, both alone and in combination with existing checkpoint inhibitors.
